Uncertainty in the Research and Development of Therapeutic Apps
First written in FY2022. 1 of 2 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023RestatedAnnual report
「Because there are limits to reducing the development risks of individual therapeutic apps, the Company plans to conduct efficient searches for promising technologies by strengthening collaboration with academic research institutions and using a therapeutic app development platform, while continuously enhancing its development pipeline.」
The Company recognizes the uncertainty in development arising from clinical trials and regulatory requirements and continues to address it through joint research and its development platform. - FY2022First statedAnnual report
「The plan may become uncertain as a result of clinical trial results, requests or guidance from regulatory authorities, or changes or revisions to relevant laws and regulations. This could lead to changes in the development strategy, delays in development, or discontinuation, and could significantly affect the Company's long-term financial condition and operating results.」
The Company explicitly identifies the risks of changes to, delays in, or discontinuation of development plans due to clinical trials, regulatory authorities, and changes in laws and regulations.